Orthopediatrics (KIDS) financial statements
Orthopediatrics reported revenue of $236M in fiscal 2025, up 22.8% a year over 9 years.
Net income was -$40M and the operating margin -16.6%, against -16.4% in 2016.
Free cash flow was -$16M.
The diluted share count rose 1245% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Orthopediatrics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37M | $46M | $58M | $73M | $71M | $98M | $122M | $149M | $205M | $236M |
| Cost of revenue | $11M | $11M | $15M | $18M | $16M | $25M | $32M | $37M | $56M | $64M |
| Gross profit | $26M | $34M | $43M | $55M | $55M | $73M | $91M | $111M | $149M | $173M |
| Research and development | $2M | $3M | $5M | $6M | $5M | $6M | $8M | $11M | $11M | $9M |
| Selling, general and admin | $28M | $37M | $48M | $58M | $70M | $86M | $104M | $126M | $167M | $193M |
| Operating income | -$6M | -$6M | -$10M | -$9M | -$27M | -$18M | -$25M | -$27M | -$35M | -$39M |
| Interest expense | $1M | $2M | $2M | $4M | $3M | $56,000 | $2M | -$198,000 | $3M | $6M |
| Pre-tax income | — | -$9M | -$12M | -$13M | -$34M | -$17M | -$4M | -$21M | -$42M | -$39M |
| Income tax | $0 | $0 | $0 | $0 | -$723,000 | -$1M | -$5M | -$338,000 | -$4M | $460,000 |
| Net income | -$7M | -$9M | -$12M | -$14M | -$33M | -$16M | $1M | -$21M | -$38M | -$40M |
| EPS (diluted) | -$7.14 | -$5.86 | -$0.96 | -$0.94 | -$1.82 | -$0.84 | $0.06 | -$0.92 | -$1.64 | -$1.69 |
| Diluted shares | 2M | 4M | 13M | 15M | 18M | 19M | 21M | 23M | 23M | 23M |
| Gross margin | 70.7% | 75.5% | 74.2% | 75.3% | 77.4% | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% |
| Operating margin | -16.4% | -14.2% | -16.6% | -12.5% | -37.6% | -18.4% | -20.8% | -18.0% | -17.1% | -16.6% |
| Net margin | -17.6% | -19.6% | -20.9% | -18.9% | -46.3% | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% |
Balance sheet
Fiscal years, from Orthopediatrics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $2M | $43M | $61M | $71M | $84M | $54M | $118M | $80M | $69M | $61M |
| Receivables | $4M | $6M | $9M | $16M | $17M | $18M | $25M | $35M | $42M | $54M |
| Inventory | — | — | $26M | $38M | $53M | $58M | $78M | $106M | $117M | $134M |
| Total current assets | $21M | $70M | $97M | $128M | $158M | $134M | $227M | $226M | $237M | $256M |
| Property, plant and equipment | $9M | $10M | $13M | $21M | $27M | $29M | $34M | $41M | $51M | $50M |
| Goodwill | — | — | $0 | $14M | $71M | $72M | $87M | $84M | $94M | $109M |
| Total assets | $31M | $82M | $112M | $182M | $320M | $304M | $428M | $439M | $473M | $509M |
| Total current liabilities | $7M | $9M | $9M | $14M | $35M | $30M | $31M | $42M | $34M | $46M |
| Long-term debt | $17M | $25M | $21M | $26M | $1M | $907,000 | $763,000 | $10M | $73M | $100M |
| Total liabilities | $25M | $35M | $30M | $40M | $86M | $79M | $49M | $62M | $119M | $162M |
| Shareholders' equity | -$65M | $47M | $82M | $142M | $235M | $225M | $379M | $377M | $355M | $347M |
| Net debt | $16M | -$17M | -$39M | -$45M | -$28M | -$7M | -$8M | -$21M | $30M | $82M |
Cash flow
Fiscal years, from Orthopediatrics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1M | -$7M | -$16M | -$18M | -$19M | -$13M | -$22M | -$27M | -$27M | -$5M |
| Capital spending | $4M | $5M | $5M | $12M | $11M | $8M | $10M | $17M | $14M | $11M |
| Free cash flow | -$5M | -$12M | -$21M | -$30M | -$29M | -$21M | -$32M | -$44M | -$41M | -$16M |
| Stock-based compensation | $1M | $3M | $3M | $3M | $6M | $6M | $7M | $11M | $14M | $18M |
| Dividends paid | $0 | $6M | $0 | $0 | — | — | — | — | — | — |
| Net borrowing | $4M | $8M | -$113,000 | $30M | $0 | $0 | $31M | $9M | $61M | $25M |
| Free cash flow margin | -14.7% | -27.2% | -36.2% | -40.8% | -40.8% | -21.6% | -26.0% | -29.5% | -20.2% | -6.8% |
| Dividends per share | — | $1.48 | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KIDS.
Open KIDS in InvestinglyQuestions
What was Orthopediatrics's revenue in 2025?
$236M in fiscal 2025, from its 10-K filing.
How much free cash flow does Orthopediatrics generate?
-$16M in fiscal 2025 (operating cash flow minus capital spending).
From Orthopediatrics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.